A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses

被引:14
作者
Beignon, AS
Brown, F
Eftekhari, P
Kramer, E
Briand, JP
Muller, S
Partidos, CD
机构
[1] CNRS, Inst Biol Mol & Cellulaire, UPR 9021, F-67084 Strasbourg, France
[2] Plum Isl Anim Dis Ctr, ARS, USDA, Greenport, NY 11944 USA
[3] Sch Med, FTD, Inst Pharmacol, F-67000 Strasbourg, France
关键词
transcutaneous immunisation; peptide vaccines; FMDV; cholera toxin; adjuvants;
D O I
10.1016/j.vetimm.2004.12.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this study a synthetic peptide representing residues 141-159 from the GH loop of VP1 protein of foot-and-mouth disease virus was tested for its capacity to elicit virus neutralising antibodies in mice after transcutaneous immunisation. Topical application of the peptide conjugated to bovine serum albumin together with cholera toxin as an adjuvant elicited anti-peptide antibody responses with strong virus neutralising activity. The combination of cholera toxin with an immunostimulatory CpG motif resulted in the induction of IgG1 and IgG2a anti-peptide antibodies with significantly enhanced virus neutralising activity. To shed more light on the mechanisms of cholera toxin adjuvanticity we demonstrated its binding to keratinocytes via GM(1)-gangliosides. This was followed by an increase of the intracellular cAMP and the rapid diffusion of cholera toxin throughout the epidermis. These findings demonstrate that peptide-based vaccines when combined with the appropriate adjuvant(s) can elicit potent virus neutralising antibody responses after transcutaneous immunisation. However, experiments in target species will be required to confirm the potential of this simple vaccination procedure in livestock. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 26 条
[1]   Immunization onto bare skin with synthetic peptides:: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells [J].
Beignon, AS ;
Briand, JP ;
Muller, S ;
Partidos, CD .
IMMUNOLOGY, 2002, 105 (02) :204-212
[2]   Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge [J].
Beignon, AS ;
Briand, JP ;
Muller, S ;
Partidos, CD .
IMMUNOLOGY, 2001, 102 (03) :344-351
[3]   Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection [J].
Berry, LJ ;
Hickey, DK ;
Skelding, KA ;
Bao, S ;
Rendina, AM ;
Hansbro, PM ;
Gockel, CM ;
Beagley, KW .
INFECTION AND IMMUNITY, 2004, 72 (02) :1019-1028
[4]   PROTECTION AGAINST FOOT-AND-MOUTH-DISEASE BY IMMUNIZATION WITH A CHEMICALLY SYNTHESIZED PEPTIDE PREDICTED FROM THE VIRAL NUCLEOTIDE-SEQUENCE [J].
BITTLE, JL ;
HOUGHTEN, RA ;
ALEXANDER, H ;
SHINNICK, TM ;
SUTCLIFFE, JG ;
LERNER, RA ;
ROWLANDS, DJ ;
BROWN, F .
NATURE, 1982, 298 (5869) :30-33
[5]   A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralizing antibodies [J].
Briand, JP ;
Benkirane, N ;
Guichard, G ;
Newman, JFE ;
vanRegenmortel, MHV ;
Brown, F ;
Muller, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (23) :12545-12550
[6]   NEW APPROACHES TO VACCINATION AGAINST FOOT-AND-MOUTH-DISEASE [J].
BROWN, F .
VACCINE, 1992, 10 (14) :1022-1026
[7]  
BROWN F, 1991, DEV BIOLOGICALS, V75, P37
[8]   The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity [J].
Enioutina, EY ;
Visic, D ;
Daynes, RA .
VACCINE, 2000, 18 (24) :2753-2767
[9]   Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge [J].
Fischer, D ;
Rood, D ;
Barrette, RW ;
Zuwallack, A ;
Kramer, E ;
Brown, F ;
Silbart, LK .
JOURNAL OF VIROLOGY, 2003, 77 (13) :7486-7491
[10]  
Glenn GM, 1998, J IMMUNOL, V161, P3211